𝙰𝙵𝚃𝙴𝚁 𝚃𝙷𝙴 $𝙽𝙳𝚃 𝙸𝙶𝙽𝙸𝚃𝙸𝙾𝙽 𝚂𝙰𝙻𝙴, 𝚆𝙷𝙰𝚃’𝚂 𝙽𝙴𝚇𝚃 𝙵𝙾𝚁 𝙽𝙴𝚄𝚁𝙾𝙻𝙰𝙱? The $NDT Ignition Sale is now behind us But for NeuroLab, this is where the next phase begins The sale was about bringing the project into the Bio ecosystem and giving the wider community a way to participate. Now the focus shifts to the part that matters most: building and validating the product The next step is Atlas NeuroLab’s roadmap starts with Atlas, planned for Q4 2026. The goal is to make its research system easier to access, with a free user tier and interactive exploration of its biomedical knowledge graph. In simple terms, users should be able to explore how compounds, targets and different parts of the brain are connected without having to manually piece everything together. Then comes Axon and Frontier Axon is focused on APIs, MCP access and integrations with other tools. That could allow NeuroLab to become part of wider research workflows rather than existing as a standalone application. Frontier takes the research side further, with plans for novel-structure and peptide inference, expanded pharmacology and stronger evidence tracking. This is where NeuroLab starts moving deeper into the actual drug-discovery process. 2027 gets even more ambitious The roadmap then moves into Workbench, which is designed around personal research libraries, saved data, compound groups and hypothesis development. After that comes Cortex, focused on deeper causal reasoning and mapping across the brain at multiple levels. And finally, Commons brings the DeSci vision closer to the research process itself, with plans for community compound submissions, prioritisation and shared IP frameworks. So the Ignition Sale was not the destination It was the funding and ecosystem milestone before the more important work begins. Now NeuroLab has to turn the roadmap into working tools, validate the technology and show researchers why this infrastructure is useful. That is the phase worth watching next You can explore and get more details here: launch.neurolabai.io/?view=r…

𝙽𝙴𝚄𝚁𝙾𝙻𝙰𝙱 𝙰𝙸 𝙸𝚂 𝙱𝚄𝙸𝙻𝙳𝙸𝙽𝙶 𝙰𝙸 𝙵𝙾𝚁 𝙽𝙴𝚄𝚁𝙾𝚂𝙲𝙸𝙴𝙽𝙲𝙴 𝚁𝙴𝚂𝙴𝙰𝚁𝙲𝙷 Drug discovery is already difficult, drug discovery for the brain is even harder because researchers have to connect molecules, receptors, cells, neural pathways and brain regions before they can understand where a compound could be useful. @NootropicsDAO_ is building a research agent that helps make those connections. Here’s what they’re building, how it could be used in real research, and why the DeSci angle matters. 🧵